Autobahn Therapeutics

Autobahn Therapeutics

  • Founded: 2017
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Depression
  • Drug types: NEU, PSY
  • Lead product: ABX-002
  • Product link:
  • Funding: $32.7M Sep 2022; $76M B Jun 2020
  • Investors: ARCH Venture Partners, Cowen Healthcare Investments, BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments, GT Healthcare

job board

Short description:

Remyelination program for multiple sclerosis

Drug notes:

Also Clin0 affective disorders; ABX-003 Clin0 undisclosed; S1P RD undisclosed

Long description:

Autobahn Therapeutics is developing regenerative medicines to treat central nervous system (CNS) disorders. Due to the high failure rate in CNS drug development Autobahn is taking a unique approach. This involves combining deep knowledge of underlying disease mechanisms and chemical manufacturing with precision medicine to develop successful therapies, whereby the most effective drugs are matched to the right patient. Autobahn’s brain-targeting chemistry platform creates orally administered small molecule prodrugs with tunable ratios of central vs. peripheral exposure allowing drug distribution profiles to be matched to disease pathophysiology. By understanding human biology, Autobahn is developing a pipeline of transformative small molecule therapies for CNS disorders.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy